Argos Therapeutics, Inc. (NASDAQ: ARGS) Tech Stack

Argos Therapeutics, Inc. (NASDAQ: ARGS) uses 8 technology products and services including SiteCatalyst, Open Graph, MySQL, and more. Explore Argos Therapeutics, Inc. (NASDAQ: ARGS)'s tech stack below.

SiteCatalyst

Analytics

Open Graph

Content Management System

MySQL

Database

Font Awesome

Font Scripts

Backbone.js

Javascript Frameworks

jQuery Migrate

Javascript Libraries

PHP

Programming Languages

Acquia Cloud Site Factory

Web Hosting

Argos Therapeutics, Inc. (NASDAQ: ARGS)'s Email Address Formats

Argos Therapeutics, Inc. (NASDAQ: ARGS) uses at least 1 format(s):

Argos Therapeutics, Inc. (NASDAQ: ARGS) Email Formats	Example	Percentage
FLast@argostherapeutics.com	JDoe@argostherapeutics.com	48%
Last@argostherapeutics.com	Doe@argostherapeutics.com	2%
First.Last@argostherapeutics.com	John.Doe@argostherapeutics.com	2%
FLast@argostherapeutics.com	JDoe@argostherapeutics.com	48%

Argos Therapeutics, Inc. (NASDAQ: ARGS) Email Formats

Example

Percentage

FLast@argostherapeutics.com

JDoe@argostherapeutics.com

48%

Last@argostherapeutics.com

Doe@argostherapeutics.com

First.Last@argostherapeutics.com

John.Doe@argostherapeutics.com

FLast@argostherapeutics.com

JDoe@argostherapeutics.com

48%

Frequently Asked Questions

Where is Argos Therapeutics, Inc. (NASDAQ: ARGS)'s headquarters located?

Argos Therapeutics, Inc. (NASDAQ: ARGS)'s main headquarters is located at 4233 Technology Drive Durham, North Carolina 27704 United States. The company has employees across 4 continents, including North AmericaEuropeAsia.

What is Argos Therapeutics, Inc. (NASDAQ: ARGS)'s phone number?

You can contact Argos Therapeutics, Inc. (NASDAQ: ARGS)'s main corporate office by phone at

+1-919-287-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Argos Therapeutics, Inc. (NASDAQ: ARGS)'s official website and social media links?

Argos Therapeutics, Inc. (NASDAQ: ARGS)'s official website is argostherapeutics.com and has social profiles on LinkedIn.

What is Argos Therapeutics, Inc. (NASDAQ: ARGS)'s SIC code NAICS code?

Argos Therapeutics, Inc. (NASDAQ: ARGS)'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Argos Therapeutics, Inc. (NASDAQ: ARGS) have currently?

As of December 2025, Argos Therapeutics, Inc. (NASDAQ: ARGS) has approximately 61 employees across 4 continents, including North AmericaEuropeAsia. Key team members include President: J. A.Associate Director Quality Assurance: K. G.Quality Assurance Manager: G. S.. Explore Argos Therapeutics, Inc. (NASDAQ: ARGS)'s employee directory with LeadIQ.

What industry does Argos Therapeutics, Inc. (NASDAQ: ARGS) belong to?

Argos Therapeutics, Inc. (NASDAQ: ARGS) operates in the Biotechnology Research industry.

What technology does Argos Therapeutics, Inc. (NASDAQ: ARGS) use?

Argos Therapeutics, Inc. (NASDAQ: ARGS)'s tech stack includes SiteCatalystOpen GraphMySQLFont AwesomeBackbone.jsjQuery MigratePHPAcquia Cloud Site Factory.

What is Argos Therapeutics, Inc. (NASDAQ: ARGS)'s email format?

Argos Therapeutics, Inc. (NASDAQ: ARGS)'s email format typically follows the pattern of FLast@argostherapeutics.com. Find more Argos Therapeutics, Inc. (NASDAQ: ARGS) email formats with LeadIQ.

When was Argos Therapeutics, Inc. (NASDAQ: ARGS) founded?

Argos Therapeutics, Inc. (NASDAQ: ARGS) was founded in 1997.

Argos Therapeutics, Inc. (NASDAQ: ARGS)

Biotechnology ResearchNorth Carolina, United States51-200 Employees

Argos Therapeutics is an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis® technology platform. Argos' most advanced product candidate, rocapuldencel-T, is being evaluated in the pivotal ADAPT Phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). In addition, rocapuldencel-T is being studied in Phase 2 investigator-initiated clinical trials as neoadjuvant therapy for renal cell carcinoma (RCC) and for the treatment of non-small cell lung cancer (NSCLC). Argos is also developing a separate Arcelis®-based product candidate, AGS-004, for the treatment of human immunodeficiency virus (HIV), which is currently being evaluated in an investigator-initiated Phase 2 clinical trial aimed at HIV eradication in adult patients.

Insights

Similar companies to Argos Therapeutics, Inc. (NASDAQ: ARGS)

Celldex Therapeutics

Moderna

BioNTech SE

Ziopharm Oncology